Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

14 Jan 2020

Abstract excerpt

Abstract Background NR2F6 has been proposed as an alternative cancer immune checkpoint in the effector T cell compartment. However, a realistic assessment of the in vivo therapeutic potential of NR2F6 requires acute depletion. Methods Employing primary T cells isolated from Cas9-transgenic mice for electroporation of chemically synthesized sgRNA, we established a CRISPR/Cas9-mediated acute knockout protocol of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31937317
DOI: 10.1186/s12964-019-0454-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapyPMID 31937317Read ↗

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6Semantic proximity Read ↗

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockadeSemantic proximity Read ↗

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapySemantic proximity Read ↗

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunitySemantic proximity Read ↗

Insights into the emerging immune checkpoint NR2F6 in cancer immunitySemantic proximity Read ↗

CRISPR/Cas9 edited tumor-associated immune cells in cancer immunotherapySemantic proximity Read ↗

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer ImmunotherapySemantic proximity Read ↗

Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradationSemantic proximity Read ↗

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapySemantic proximity Read ↗

CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastomaSemantic proximity Read ↗

Targeting a check point receptor of human primary natural killer cells via CRISPR/Cas9 potentiates anti-tumor activity in allogeneic glioblastomaSemantic proximity Read ↗

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.